• Publications
  • Influence
Improved survival with ipilimumab in patients with metastatic melanoma.
TLDR
Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Expand
A Landscape of Driver Mutations in Melanoma
TLDR
The spectrum of driver mutations provided unequivocal genomic evidence for a direct mutagenic role of UV light in melanoma pathogenesis, providing oncogenic insights in BRAF- and NRAS-driven melanoma as well as those without known NRAS/BRAF mutations. Expand
Nivolumab in previously untreated melanoma without BRAF mutation.
TLDR
Nivolumab was associated with significant improvements in overall survival and progression-free survival, as compared with dacarbazine, among previously untreated patients who had metastatic melanoma without a BRAF mutation. Expand
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
TLDR
Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation in a phase 3 randomized clinical trial. Expand
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
TLDR
Investigating the roles of tumor-specific neoantigens and alterations in the tumor microenvironment in the response to ipilimumab found no recurrent neoantigen peptide sequences predicted responder patient populations, suggesting detailed integrated molecular characterization of large patient cohorts may be needed to identify robust determinants of response and resistance to immune checkpoint inhibitors. Expand
TERT Promoter Mutations in Familial and Sporadic Melanoma
TLDR
A melanoma-prone family through linkage analysis and high-throughput sequencing was investigated and a disease-segregating germline mutation in the promoter of the telomerase reverse transcriptase (TERT) gene, which encodes the catalytic subunit of telomersase, caused up to twofold increase in transcription. Expand
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
TLDR
Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipILimumab alone, and in patients with PD-L1-negative tumors, the combination of PD-1 and CTLA-4 blockade was more effective than either agent alone. Expand
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
TLDR
Vaccination with autologous DCs generated from peripheral blood is a safe and promising approach in the treatment of metastatic melanoma and antigen-specific immunity was induced during DC vaccination. Expand
Improved overall survival in melanoma with combined dabrafenib and trametinib.
TLDR
Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF V600E or V600K mutations, without increased overall toxicity. Expand
Comprehensive Characterization of Cancer Driver Genes and Mutations
TLDR
This study reports a PanCancer and PanSoftware analysis spanning 9,423 tumor exomes (comprising all 33 of The Cancer Genome Atlas projects) and using 26 computational tools to catalog driver genes and mutations, identifying 299 driver genes with implications regarding their anatomical sites and cancer/cell types. Expand
...
1
2
3
4
5
...